CDNA

CareDx, Inc.

CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient\'s lifetime.

CareDx, Inc. (CDNA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C-
Factor Score 1.9 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 34.1
EV / EBITDA 157.0
Rev Growth YoY 39.3%
Gross Margin 71.0%
Price Return 3M 70.7%
Price Return 12M 417.1%
Catalyst Signal 0.00
Market Cap $4.2B
TTM Revenue $497.4M
Price / Sales 8.5
ROE 33.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C- (1.9) C (2.2) B- (2.9) B+ (3.8) C+ (2.6) C+ (2.7)
2026-11-04 C- (1.9) C (2.2) B- (2.9) A- (3.9) C+ (2.7) C+ (2.7)
2026-10-28 C- (1.9) C+ (2.5) B- (2.9) A (4.5) C+ (2.7) B- (2.9)
2026-10-21 C- (1.9) C+ (2.5) B- (2.9) A- (4.1) C+ (2.6) C+ (2.8)
2026-10-14 C- (1.9) C+ (2.5) B- (2.9) A+ (4.9) C+ (2.6) B- (3.0)
Page 1 of 8
…